Tamsil

Basic Tamsil Information

• INN (International Nonproprietary Name): Terbinafine
• Brand Names Available In Australia: not specified
• ATC Code: D01BA02
• Forms & Dosages: Oral tablet 250 mg; Cream 1%; Topical spray 1%.
• Manufacturers In Australia: not specified
• Registration Status In Australia: Listed by TGA Australia as prescription-only (Rx).
• OTC / Rx Classification: Oral tablet — Prescription-only (Rx). Topical forms — available OTC in some jurisdictions; classification varies by market.

Latest Research Findings

Patients and prescribers ask: does terbinafine still lead the pack for dermatophyte infections?

Recent Austrian and EU clinical data from 2022–2025 reinforce terbinafine’s role as a first-line allylamine for dermatophyte infections.

Multicentre European trials and meta-analyses report consistent mycological cure rates for oral terbinafine in onychomycosis, especially toenail infections, when given as 250 mg once daily for 6–12 weeks.

Comparative randomised controlled trials commonly show terbinafine outperforms itraconazole for dermatophyte eradication, although local susceptibility patterns can vary.

EMA pharmacovigilance and national reporting systems, including Austria’s Meldesysteme, continue to flag rare but serious hepatic adverse events and taste disturbance signals.

Those safety signals remain uncommon relative to overall prescription volumes according to pooled post-marketing surveillance.

Real-world Austrian registry analyses using E‑Medikation and e‑card aggregated datasets (2023–25) show good adherence to guideline durations for skin tinea, while adherence for onychomycosis is lower and contributes to recurrences.

Key product forms recorded in these datasets include oral tablets 250 mg and topical 1% cream or spray.

Key RCTs Summary

Pharmacovigilance Highlight

EMA and national reports document rare serious hepatic events and taste disturbances, with overall rates low versus prescription volumes.

This evidence level: multiple RCTs plus EMA post-marketing surveillance.

Clinical Effectiveness In Austria

Patients often want to know whether terbinafine works the same in local clinics as in trials.

Austrian clinical practice data show terbinafine, both oral and topical, delivers reliable outcomes when prescribed and adhered to.

Sozialversicherung prescription datasets and pharmacy e‑Medikation logs confirm terbinafine 250 mg is the dominant oral antifungal dispensed for dermatophyte nail and skin infections in urban centres.

Rural dispensing patterns indicate higher topical use where access to systemic therapy or specialist review is slower or where patients prefer topical treatment.

Reported cure and relapse rates in Austrian outpatient audits align with EU averages: continuous oral terbinafine gives better mycological clearance for toenail disease but cosmetic nail improvement follows nail growth.

Outpatient dermatology notes attribute some treatment interruptions to liver-test abnormalities or taste disturbance, with pharmacies fielding frequent counselling requests about hepatic monitoring and interactions.

Standard treatment durations recorded in Austrian practice follow common guidance: onychomycosis 6–12 weeks; tinea corporis/cruris 2–4 weeks; tinea pedis 2–6 weeks.

Registry metrics commonly tracked in Austria include prescription volumes, adherence percentage and frequency of lab monitoring at baseline and during therapy.

Urban Vs Rural Dispensing (Summary)

Indications And Extended Uses

People ask: what is terbinafine officially for, and when is it used off-label?

Approved indications in Austria and under EMA guidance include onychomycosis (dermatophyte nail infections), tinea corporis, tinea cruris and tinea pedis.

Topical terbinafine 1% cream or spray is widely used for superficial dermatophyte and interdigital infections, and is OTC in some EU countries though in Austria oral forms are prescription-only.

Off-label applications seen in Austrian clinics include adjunctive oral use for persistent or recurrent scalp dermatophyte infections in adults after mycological confirmation.

When infections are recurrent or atypical, Austrian practice prioritises laboratory confirmation with KOH microscopy or culture before systemic therapy to guide treatment and reimbursement.

Typical topical regimen is a thin layer applied once to twice daily for 1–4 weeks, while oral regimens use 250 mg once daily for the designated duration.

Indication Versus Dose

Approved Vs Off-Label

• Approved: Nail and common skin dermatophyte infections.
• Off‑label: Specialist-guided uses after diagnostic confirmation, e.g. persistent scalp dermatophytes in adults.

Composition And Brand Overview

Customers frequently ask whether brand matters and what is in the pack.

INN: Terbinafine. ATC: D01BA02.

The original brand Lamisil® appears in many markets alongside generics produced by multinational and regional manufacturers such as Sandoz, Zentiva, Krka, Teva and Stada.

Typical packaging formats recorded include oral tablets 250 mg in 7, 14, 28 or 30 tablet packs, cream 1% in 7, 15 or 30 g tubes, and sprays 1% in 15–30 ml bottles.

Apotheken and wholesalers usually list manufacturer and batch details on the box which pharmacists check before dispensing and when advising on reimbursement.

Patients often ask about brand preference or cheaper generics; Austrian pharmacist guidance is to rely on bioequivalence assurance when substituting generics.

Brands And Pack Sizes

Excipient Cautions

• Check for known hypersensitivity to excipients listed on the pack.
• Patients with severe allergy histories should discuss alternatives with the prescriber or pharmacist.

Contraindications And Special Precautions

Common questions: who must avoid oral terbinafine, and what needs monitoring?

Absolute contraindications include known hypersensitivity to terbinafine or formulation excipients and chronic or active liver disease.

Relative contraindications include pre-existing mild hepatic impairment, moderate to severe renal impairment (CrCl <50 mL/min), pregnancy and lactation where oral use is generally avoided, and autoimmune diseases such as lupus or severe psoriasis which may be exacerbated.

Terbinafine inhibits CYP2D6, so caution is required with psychotropic drugs, certain beta-blockers and other CYP2D6 substrates commonly flagged in E‑Medikation checks.

Austrian safety guidance emphasises baseline liver function tests before oral therapy and prompt cessation with jaundice, dark urine or persistent nausea.

Occupational advice: avoid roles that require precise taste discrimination or heavy machinery operation if dizziness or severe taste disturbance occur.

Definitions

• Absolute Contraindication: Condition where terbinafine must not be used (e.g. active liver disease).
• Relative Contraindication: Use only with caution, monitoring, or dose adjustment (e.g. renal impairment).

Immediate Red Flags Requiring Cessation

Jaundice, dark urine, severe abdominal pain, signs of anaphylaxis, or unexplained severe fatigue should prompt immediate stopping and urgent medical review.

Dosage Guidelines

Patients commonly ask: how should I take terbinafine for nails or skin?

Standard adult oral dosing in Austria is terbinafine 250 mg once daily for indicated durations.

Typical durations are 6 weeks for fingernail onychomycosis and 12 weeks for toenail disease, and 2–4 weeks for tinea corporis or cruris and 2–6 weeks for tinea pedis.

Topical dosing uses terbinafine 1% cream or spray applied thinly once or twice daily for 1–4 weeks depending on site and severity.

Dosing adjustments include specialist weight-based dosing in children (oral use not routinely recommended under 18), no routine elderly adjustment but increased monitoring, 50% dose reduction or avoidance in CrCl <50 mL/min, and avoidance in hepatic impairment.

Missed-dose advice: take as soon as remembered unless close to the next dose; do not double up.

Quick Dose Table

Baseline Monitoring Checklist

• Baseline liver function tests before oral therapy.
• Renal function assessment if indicated.
• Medication review for CYP2D6 interactions via e‑card/E‑Medikation.

Overview Of Interactions

People often ask which medicines to avoid with terbinafine.

Terbinafine’s main interactions stem from CYP2D6 inhibition and hepatic metabolism.

Concomitant use with CYP2D6 substrates such as some antidepressants, antipsychotics and certain beta-blockers can raise plasma levels of those drugs.

Austrian E‑Medikation audits commonly flag psychiatric medications as interaction risks with terbinafine.

While grapefruit interactions are not a principal issue for terbinafine, pharmacists still check the full medicine list in the e‑card record before dispensing.

Alcohol does not have a formal pharmacokinetic interaction but increases hepatic risk and patients are counselled to minimise alcohol during therapy.

Potent CYP inducers can reduce terbinafine efficacy and should be reviewed with the prescriber.

High‑Risk Drug Classes

• Antidepressants and antipsychotics that are CYP2D6 substrates.
• Certain beta-blockers metabolised via CYP2D6.
• Other CYP2D6 substrate medicines where plasma level changes have clinical impact.

Pharmacists routinely run e‑card E‑Medikation checks and liaise with prescribers where interaction alerts arise.

Cultural Factors And Patient Behaviour

Patients commonly worry about access, costs and whether brand or country of purchase matters.

Rezeptpflicht for systemic terbinafine, the e‑card E‑Medikation system, and a strong pharmacy counselling tradition mean many people consult Apotheken first for advice.

Urban centres such as Vienna and Graz have rapid access to dermatologists and full prescription services, whereas rural areas often rely on local Apotheken and family doctors leading to occasional delays before systemic therapy.

Cross‑border shopping in regions near Germany, the Czech Republic or Hungary occurs for perceived price differences or quicker OTC topical access, and pharmacists advise checking packaging and manufacturer details.

Pharmacy chains and the Österreichische Apothekerkammer influence patient education and substitution guidance, and online communities commonly express concerns about liver safety and treatment length.

Access Differences

• Urban: faster specialist access, higher oral terbinafine dispensing.
• Rural: greater topical use, more pharmacist-led management.

Common Patient Misconceptions To Address

• “Topical always beats pills” — clarify when systemic therapy is needed.
• “Immediate cosmetic cure” — explain nail growth delays after mycological cure.
• “Foreign packs are always better/cheaper” — check for authorised packaging and batch data.

Availability And Price Overview

Patients ask whether tamsil is easy to buy and whether it is covered by Sozialversicherung.

Systemic terbinafine tablets are prescription-only in Austria, and topical 1% forms may be OTC in some jurisdictions but often dispensed through Apotheken.

Manufacturers active in the market include the original Novartis lineage and multiple generics such as Sandoz, Zentiva, Krka and Teva.

Pricing and reimbursement under Sozialversicherung vary; reimbursement is more likely for clinically justified systemic therapy with diagnostic confirmation but many uncomplicated cases remain out-of-pocket.

Pharmacy chains and online Apotheken offer competitive pricing, and cross‑border purchasers may find lower list prices but should consider labelling and counselling differences.

Storage guidance used in practice is to store at 15–30°C and protect from moisture.

In our online pharmacy, tamsil is available without a prescription, with discreet delivery to Australia in 5–14 days.

Typical Pack Prices (Local Estimate)

Reimbursement Checklist

• Provide culture or KOH confirmation where available.
• Document indication and prior topical treatment failures for Sozialversicherung claims.

Comparable Medicines And Preferences

Patients often compare terbinafine with itraconazole or topical solutions.

Alternatives in Austria include itraconazole and fluconazole orally, and topical options such as ciclopirox and efinaconazole when available.

Terbinafine is fungicidal against dermatophytes via squalene epoxidase inhibition and is often preferred for dermatophyte onychomycosis due to higher mycological cure rates.

Itraconazole can be useful for mixed infections or non‑dermatophyte moulds and has both continuous and pulse regimens.

Fluconazole is sometimes considered but has variable efficacy for dermatophytes, while topical ciclopirox or efinaconazole are options for mild onychomycosis or when systemic therapy is contraindicated.

Choice in Austrian practice depends on pathogen identification, patient comorbidities including hepatic or renal disease, potential drug interactions, and Sozialversicherung reimbursement rules.

Comparison Table

Frequently Asked Questions (Austrian Pharmacy Context)

Q: Is oral terbinafine safe for my liver?

A: Baseline liver function tests are recommended before starting oral terbinafine; avoid if chronic liver disease is present and stop with jaundice or dark urine.

Q: Can I drink alcohol while taking terbinafine?

A: Alcohol increases hepatic load and patients are advised to minimise alcohol during treatment.

Q: Will terbinafine affect my ability to drive or work?

A: Most people are unaffected, but dizziness or severe taste disturbance can occur and you should avoid heavy machinery if symptomatic.

Q: Is terbinafine covered by Sozialversicherung?

A: Reimbursement depends on clinical justification; providing culture/KOH results and clear indication improves the likelihood of coverage.

When To Seek Urgent Care

Seek urgent medical review for jaundice, dark urine, severe abdominal pain, signs of anaphylaxis or sudden marked fatigue.

Guidelines For Correct Use

Patients and pharmacists ask what standard counselling should include.

Follow Österreichische Apothekerkammer standards: confirm the indication, review the e‑card medication list for interactions and advise baseline LFTs for oral treatment.

For oral terbinafine explain 250 mg once daily dosing, expected treatment duration (6–12 weeks for nails), missed-dose rules and side-effect red flags like jaundice or severe rash.

For topical formulations instruct applying a thin layer 1–2 times daily, continuing the full course until lesions resolve even if symptoms improve, and storing products at 15–30°C.

Provide written advice on alcohol minimisation and perform an e‑card check for interactions prior to dispensing.

If a patient has bought product cross‑border, verify packaging and manufacturer details before advising on use.

Dispensing Checklist

• Confirm diagnosis and, where applicable, have mycological confirmation for Sozialversicherung.
• Check baseline LFTs and renal function as required.
• Run e‑card interaction check and counsel on side effects.

Patient Leaflet Template (Localised)

Include: indication, dose schedule, duration, LFT advice, interaction warnings, storage, and Sozialversicherung/Rezeptpflicht notes.

Delivery Across Australia